MX2018016419A - Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida. - Google Patents

Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.

Info

Publication number
MX2018016419A
MX2018016419A MX2018016419A MX2018016419A MX2018016419A MX 2018016419 A MX2018016419 A MX 2018016419A MX 2018016419 A MX2018016419 A MX 2018016419A MX 2018016419 A MX2018016419 A MX 2018016419A MX 2018016419 A MX2018016419 A MX 2018016419A
Authority
MX
Mexico
Prior art keywords
compounds
phenyl
substituted
kinase inhibitors
sulfonamide derivatives
Prior art date
Application number
MX2018016419A
Other languages
English (en)
Inventor
MOTTO Ilaria
Bindi Simona
CARENZI Davide
Pulici Naurizio
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of MX2018016419A publication Critical patent/MX2018016419A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a compuestos de N-(sustituida-fenil)-sulfonamida, los cuales son extremadamente útiles como inhibidores de las proteínas quinasas (por ejemplo. quinasa PERK) y, en consecuencia, pueden ser empleadas para el tratamiento de desórdenes celulares proliferativos, como el cáncer, o enfermedades asociadas con vías de respuesta a proteinas desplegadas activadas, como la enfermedad de Alzheimer. La presente invención también proporciona métodos para preparar dichos compuestos, composiciones farmacéuticas que los comprenden, así como métodos para el tratamiento de enfermedades, utilizando dichas composiciones farmacéuticas.
MX2018016419A 2016-06-21 2017-06-19 Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida. MX2018016419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16175386 2016-06-21
PCT/EP2017/064904 WO2017220477A1 (en) 2016-06-21 2017-06-19 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2018016419A true MX2018016419A (es) 2019-09-09

Family

ID=56148248

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016419A MX2018016419A (es) 2016-06-21 2017-06-19 Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.

Country Status (18)

Country Link
US (4) US10561660B2 (es)
EP (1) EP3472165B1 (es)
JP (1) JP6867417B2 (es)
KR (1) KR102500416B1 (es)
CN (1) CN109311894B (es)
AU (1) AU2017279878B9 (es)
CA (1) CA3029097A1 (es)
DK (1) DK3472165T3 (es)
ES (1) ES2964781T3 (es)
FI (1) FI3472165T3 (es)
HU (1) HUE064919T2 (es)
IL (1) IL263739B (es)
MX (1) MX2018016419A (es)
PL (1) PL3472165T3 (es)
PT (1) PT3472165T (es)
RU (1) RU2753520C2 (es)
SI (1) SI3472165T1 (es)
WO (1) WO2017220477A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3472165T (pt) 2016-06-21 2023-12-12 Nerviano Medical Sciences Srl Derivados de n-(fenil substituído)-sulfonamida como inibidores da quinase
WO2021030238A2 (en) * 2019-08-09 2021-02-18 Ohm Oncology Method of synthesis of compound for dual inhibition of jak2 and bet
KR20210056827A (ko) * 2019-11-11 2021-05-20 일동제약(주) 신규한 벤젠설폰아미드 유도체 및 그의 용도
CN115768750A (zh) * 2020-02-17 2023-03-07 阿莱斯塔治疗公司 Gcn2调节剂化合物
MX2022013984A (es) 2020-05-08 2023-01-30 Halia Therapeutics Inc Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
CN111454261A (zh) * 2020-05-27 2020-07-28 南京普锐达医药科技有限公司 一种4-氯吡咯并嘧啶化合物的合成方法
EP4247795A1 (en) 2020-11-18 2023-09-27 Deciphera Pharmaceuticals, LLC Gcn2 and perk kinase inhibitors and methods of use thereof
WO2022212326A1 (en) 2021-03-29 2022-10-06 Halia Therapeutics, Inc. Nek7 inhibitors
CA3214042A1 (en) 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors
WO2023025912A1 (en) 2021-08-25 2023-03-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
WO2023102228A1 (en) * 2021-12-03 2023-06-08 Deciphera Pharmaceuticals, Llc Heterocyclic compopunds as gcn2 and perk kinase inhibitors
WO2023196659A1 (en) * 2022-04-08 2023-10-12 Alesta Therapeutics BV Gcn2 modulator compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL131582A0 (en) * 1997-03-19 2001-01-28 Basf Ag Pyrrolo [2,3d] pyrimidines and their use as tyrosine kinase inhibitors
SK3852001A3 (en) * 1998-09-18 2003-03-04 Basf Ag 4-Aminopyrrolopyrimidines as kinase inhibitors
GB0625827D0 (en) * 2006-12-22 2007-02-07 Astex Therapeutics Ltd New compounds
DK2358720T3 (en) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
PE20150637A1 (es) * 2012-10-16 2015-05-08 Almirall Sa Derivados de pirrolotriazinona como inhibidores de pi3k
US9688662B2 (en) 2013-04-04 2017-06-27 Janssen Pharmaceutica Nv N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
SG11201509338QA (en) * 2013-05-30 2015-12-30 Plexxikon Inc Compounds for kinase modulation, and indications therefor
JP2017507967A (ja) * 2014-03-11 2017-03-23 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｐｅｒｋ阻害剤として作用する化合物
PT3472165T (pt) * 2016-06-21 2023-12-12 Nerviano Medical Sciences Srl Derivados de n-(fenil substituído)-sulfonamida como inibidores da quinase

Also Published As

Publication number Publication date
IL263739A (en) 2019-01-31
AU2017279878A1 (en) 2019-01-31
EP3472165B1 (en) 2023-09-06
CN109311894A (zh) 2019-02-05
AU2017279878B9 (en) 2021-04-29
HUE064919T2 (hu) 2024-04-28
EP3472165A1 (en) 2019-04-24
RU2753520C2 (ru) 2021-08-17
KR102500416B1 (ko) 2023-02-17
US11491158B2 (en) 2022-11-08
AU2017279878B2 (en) 2021-04-01
KR20190020104A (ko) 2019-02-27
RU2019101002A (ru) 2020-07-21
FI3472165T3 (fi) 2023-12-11
US11833153B2 (en) 2023-12-05
SI3472165T1 (sl) 2024-02-29
DK3472165T3 (da) 2023-12-11
PT3472165T (pt) 2023-12-12
US20200121686A1 (en) 2020-04-23
US20190201406A1 (en) 2019-07-04
US20210128563A1 (en) 2021-05-06
CA3029097A1 (en) 2017-12-28
US10561660B2 (en) 2020-02-18
US20230107393A1 (en) 2023-04-06
PL3472165T3 (pl) 2024-05-27
RU2019101002A3 (es) 2020-09-30
JP6867417B2 (ja) 2021-04-28
US10918642B2 (en) 2021-02-16
ES2964781T3 (es) 2024-04-09
JP2019521996A (ja) 2019-08-08
WO2017220477A1 (en) 2017-12-28
CN109311894B (zh) 2022-03-22
IL263739B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
MX2018016419A (es) Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.
EA201792047A1 (ru) Новые соединения
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
EA201990019A1 (ru) Соединения и композиции для подавления активности shp2
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
MX2018012609A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
BR112018071585A2 (pt) formulações de um inibidor de lsd1
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2015013481A (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
MX342509B (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
JO3458B1 (ar) 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.